Efficacy and safety of fixed‐dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial

This study evaluated the efficacy and safety of 26 weeks of twice‐daily (BID) alogliptin + metformin fixed‐dose combination (FDC) therapy in Asian patients with type 2 diabetes. Patients aged 18 to 75 years with hemoglobin A1c (HbA1c) of 7.5% to 10.0% after ≥2 months of diet and exercise and a 4‐wee...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Linong, Li, Ling, Kuang, Jian, Yang, Tao, Kim, Dong‐Jun, Kadir, Azidah A., Huang, Chien‐Ning, Lee, Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412676/
https://www.ncbi.nlm.nih.gov/pubmed/28075066
http://dx.doi.org/10.1111/dom.12875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412676/
https://www.ncbi.nlm.nih.gov/pubmed/28075066
http://dx.doi.org/10.1111/dom.12875

Ejemplares similares